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Short Report
Introduction
The treatment of symptoms in borderline personality disorder
(BPD), including aggression, has been studied intensively
(Zanarini, 2004). The efficacy of selective serotonin reuptake
inhibitors, atypical neuroleptics and with the exception of valproate
and carbamazepine, anti-epileptic drugs in the treatment of patho-
logical aggression remains to be established (Fava, 1997; Azouvi
et al., 1999; Tariot et al., 1998; Nickel et al., 2004; Nickel et al.,
2005; Loew et al., 2006; Nickel et al., 2006). Effective pharmaco-
logical interventions with lamotrigine, an anti-convulsant, in bor-
derline patients have also been reported (Pinto and Akiskal, 1998;
Preston et al., 2004); however, until now, only one controlled trial
is known, which employed this medication for patients with BPD
(Tritt et al., 2005). That study was carried out in a double-blind and
placebo-controlled design with women with BPD (Tritt et al.,
2005), and after eight weeks’ treatment with a daily dose of up to
200 mg lamotrigine, significant changes on most scales of the
State-Trait Anger Expression Inventory (STAXI) (Schwenkmezger
et al., 1992) were observed. In the present, follow-up observation
of patients who participated in the above-mentioned study (Tritt
et al., 2005), the longer-term influence of lamotrigine on anger
symptoms in women with BPD was investigated.
Methods
The procedure for recruitment of the study sample has already 
been described in detail in our first report (Tritt et al., 2005).
The exclusion criteria for the follow-up observation were schiz-
ophrenia, current use of psychotropic medication in the previous
placebo group (PG), termination of lamotrigine in the lamotrigine
group (LG), as well as current psychotherapy, current suicidal
ideation, severe somatic illness or abuse of drugs or alcohol in
either group. Potential subjects were also excluded if they were
pregnant, planning to be, or not using contraception. During the
course of the follow-up study, additional subjects were excluded
who missed more than one evaluation.
The subjects were invited to participate in face-to-face interviews.
The possible side effects were fully explained once again. Primary
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outcome measures were changes in the STAXI (Schwenkmezger
et al., 1992), described in detail elsewhere (Tritt et al., 2005).
The necessary sample size calculation and the randomization
were described in detail, in our report of the the first study, in which
female patients were treated for eight weeks in 2004 with a daily
dose of up to 200 mg lamotrigine (LG: n  18) or with a placebo
(PG: n  9), and tested with STAXI every week (Tritt et al., 2005).
Following the final testing, the blind was broken.
After completion of the above-mentioned study, an 18-month
follow-up was carried out, in which the patients (LG: n  18;
former [Ex-PG]: n  9) were tested every six months. The
patients in the LG took continued taking 200 mg lamotrigine
daily. The Ex-PG took neither lamotrigine nor placebo. During
the course of the trial, the intermediate results were not analysed.
After eighteen months, both groups were tested for the last time
and physically examined. Ten subjects dropped out; of these, 
two were from the PG and one from the LG during the placebo-
controlled study (Tritt et al., 2005), and seven dropped out
during the follow-up: two who missed more than one evaluation
(one from the LG), one from the LG who changed residence, one
from the LG due to termination of lamotrigine, and three from
the Ex-PG due to initiation of therapy with lamotrigine or anoth-
er psychopharmica. The test-questionnaires were filled out by 
the patients both independently and anonymously. Our staff
checked the data for completeness. The study was concluded
according to plan.
Data analysis
We used the statistical program SPSS, Version 12 (SPSS Inc.
Chicago, Illinois, USA) to analyse the data according to the
intend-to-treat principle. Data are presented as means and standard
deviations.
A two-factor repeated measure analysis of variance was
performed. The treatment condition was defined as the between-
subject factor, and the measurements in time as the within-subject
factor. When the assumptions for performing the repeated measure
analysis were not given, the results were adjusted using the
Greenhouse-Geisser Epsilon (Stevens, 1992). To assess whether
there were differences at the initial and final points, multiple
comparisons were performed using contrasts for each treatment
condition. The significance levels were corrected using the
Bonferroni correction. Changes in the dichotomy parameters,
employment and partnership were analysed by means of the
binominal test (Dufner et al., 1992).
Source of funding and ethical considerations
The study was planned and conducted in accordance with the
Declaration of Helsinki and ethical laws pertaining to the medical
professions and its design approved by the clinic’s ‘Ethikkomission’
(the German equivalent of the Committee on Human Subjects). All
subjects gave written informed consent. The study was conducted
independent of any institutional influence and was not funded. There
were no conflicts of interest.
Results
The detailed medical and social data from the patients of both
groups were described and compared with each other in the
previous publication (Tritt et al., 2005).
Table 1 summarizes the changes in both groups over the course
of the entire study. The LG experienced a significantly greater
changes than the placebo/Ex-PG on all STAXI scales.
No serious side effects were observed. In isolated cases,
relatively mild rash, dizziness, headache and nausea were reported.
Two subjects from the Ex-PG and one from the LG engaged in 
self-mutilation, and one from the Ex-PG attempted suicide during
the study. In addition, weight loss was observed after eighteen
months treatment. In the LG, weight loss was no more significant
than in the (PG) [LG: starting weight MV  78.6  10.1 kg,
weight after 18 months MV  77.8  11.9 kg; Ex-PG: starting
weight MV  77.3  11.4 kg, BMI  26.8, weight after 18
months MV  78.5  13.7 kg; p(IE)  0.65, p(FE)  0.01, 
P (group  time effect)  0.43, P (group effect)  0.31].
Discussion
During the entire observation period, there was a significantly
greater change on all STAXI scales (Schwenkmezger et al., 1992)
in the lamotrigine-treated group that in the placebo/ex-PG.
Specifically, lamotrigine was more effective in treating the aggres-
sion component of borderline psychopathology, which corroborates
the previous report (Tritt et al., 2005). Among our patients, lamot-
rigine appeared to influence the intensity of the perceived feeling of
anger as well as the threshold for perceiving it. The way aggression
was processed intra-psychologically was possibly also influenced,
and in the final analysis even the socially desirable control of anger
as well.
The most common side effects of lamotrigine are headache,
nausea, dizziness, infection, dry mouth, diarrhea, somnolence,
ataxia, tremor, insomnia, rash and withdrawal (Messenheimer
et al., 1998). All our patients tolerated it well or very well; unpleas-
ant symptoms were reported only in isolated cases. Moderate
weight loss was observed and was usually regarded as beneficial. In
the literature, both moderate weight loss and mood stabilization
have been attributed to lamotrigine (Calabrese, 2003). However,
our study could only demonstrate that weight remained constant
with lamotrigine.
The results of this trial are consistent with those of earlier stud-
ies which found that anti-convulsant medications are effective in
the treatment of pathologic aggression (Fava, 1997; Azouvi et al.,
1999; Tariot et al., 1998). Rizvi (2002) and Pinto and Akiskal
(1998) reported decreased symptoms of aggression in borderline
patients undergoing lamotrigine therapy.
One of the limitations was that the sample size was relatively
small, and both the blind and placebo medication were discontin-
ued. In addition, the relatively high dropout rate limits the extent
to which the results can be generalized. The study focused on only
one dimension of BPD in borderline women, namely, aggressive-
impulsivity. The effects of lamotrigine on other dimensions of
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BPD, such affective dysregulation, cognitive perceptual impair-
ment and disturbed relationships, were not evaluated. Additional
placebo-controlled trials of longer duration are needed to see if
these results can be replicated.
Following a longer period of observation, lamotrigine appears
to be a safe and effective agent for improving aggression in
borderline women (Tritt et al., 2005), and the treatment effect
ascertained in a placebo-controlled study (Tritt et al., 2005) could
be corroborated in this subsequent observational study. The results
of this trial corroborates other reports in which anti-convulsants
(Tariot et al., 1998, Nickel et al., 2004; Nickel et al., 2005; 
Tritt et al., 2005) were found to be effective in the treatment of
pathologic aggression.
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